The gut microbial metabolite butyrate can promote anti‐tumour therapeutic efficacy through inhibitor of DNA binding 2‐dependent modulation of CD8+ T cell immunity, suggesting that gut microbial metabolites may be effective as part of cancer therapy.218. The gene discussed is CD8A; the disease is cancer.